PT-141 (Bremelanotide): An Approved Drug and a Research Chemical at the Same Time

PT-141 is bremelanotide, approved in the US in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. The labelled dose is 1.75 mg by subcutaneous autoinjector, taken as needed rather than on a schedule.

It is simultaneously sold as a research chemical in multi-milligram vials. Those two things share a molecule and very little else — different manufacturing, different quality assurance, and a labelled dose that applies to one population studied under supervision.

How it works

PT-141 is a melanocortin receptor agonist. Unlike PDE5 inhibitors, which act on the vascular system, it acts centrally on pathways in the brain involved in sexual desire — a different mechanism addressing a different part of the problem.

It is a metabolite of melanotan II, which is why the two are related and why some of the same side effects appear. Bremelanotide was developed specifically for this indication rather than for pigmentation.

Reported side effects

The trial programme reported a consistent profile, dominated by:

• Nausea, the most common effect and the most frequent reason for discontinuation in trials.

• Flushing and headache.

• Injection site reactions.

• Transient blood pressure changes — a small increase with a compensatory heart rate decrease, which is why the label addresses cardiovascular considerations.

• Focal hyperpigmentation with repeated use, reflecting melanocortin receptor activity.

The vial math

Research vials are typically 10 mg — several times the labelled single dose — so concentration choice matters a great deal here.

The peptide calculator converts any vial and target into units.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

Is PT-141 the same as Viagra?

No. PDE5 inhibitors act on blood flow; PT-141 acts on central melanocortin pathways. Different mechanisms, different targets.

Is it approved for men?

The US approval is for hypoactive sexual desire disorder in premenopausal women. Use outside that population sits outside the approval and the trial evidence.

Why does it cause skin darkening?

Melanocortin receptors are involved in pigmentation as well as sexual response, so activity at those receptors can produce both effects. It is the same receptor family that makes melanotan II a tanning compound.